Drug Profile
Ziprasidone - Pfizer
Alternative Names: Captisol-enabled IV-Ziprasidone; CP-88059-01; CP-88059-1; Geodon; ME-2112; RQ-00000003; Zeldox; Ziprasidone hydrochloride; Ziprasidone mesylateLatest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Meiji Seika Pharma; Pfizer; RaQualia Pharma
- Class Antipsychotics; Mood stabilisers; Piperazines; Thiazoles
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bipolar disorders; Schizophrenia
- No development reported Anxiety disorders; CNS disorders
- Discontinued Bipolar depression
Most Recent Events
- 03 Jan 2024 No development reported - Phase-III for Bipolar disorders (In adolescents, In children) in Philippines (PO)
- 03 Jan 2024 No development reported - Phase-III for Bipolar disorders (In adolescents, In children) in Ukraine (PO)
- 03 Jan 2024 No development reported - Phase-III for CNS disorders in Japan (unspecified route)